Skip to main content

Pipeline And Milestones

Breaking Boundaries Engineering The Future of Targeted Medicines
Platform Candidate Program Area
Pre-Clinical
Phase 1
Phase 2
Phase 3
 Status Partner Next Milestone
Vascular Targeting System (VTS)
Gene-Based Therapy
 Ofra-Vec (ofranergene obadenovec: 'VB-111') Platinum Resistant Ovarian Cancer (PROC)
Phase 3
Registration Enabling Study (OVAL)
Status: Fully Enrolled
GOG Foundation
 Fully Enrolled Nano-Carrier (Japan) Wholly-owned ROW PFS Readout (Primary Endpoint) - 2H22 OS Readout (Primary Endpoint) - 2023
Recurrent Glioblastoma
Phase 2
Randomized Controlled Study
Status: Recruiting
UCLA Memorial Sloan Kettering Cancer Center Dana Farber Cancer Institute UT Health San Antonio
 Recruiting Preliminary Data - 2022
Colorectal Cancer
Phase 2
Nivolumab Combo
Status: Recruiting
National Cancer Institute
 Recruiting Preliminary Data - 2022
Monocyte Targeting Technology (MTT)
Monoclonal Antibodies
 VB-601 Anti-inflammatory
Phase 1
Status: IND Enabling Studies
 IND Enabling Studies Wholly-owned First in Human - 2H22